APA (7th ed.) Citation

Weichenthal, M., Gavrilova, I., Mangana, J., Leiter-Stoppke, U., Ellebaek, E., Ruhlmann, C., . . . Schadendorf, D. (2025). 1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study. Annals of Oncology, 36, S963. https://doi.org/10.1016/j.annonc.2025.08.2251

Chicago Style (17th ed.) Citation

Weichenthal, M., et al. "1623P Impact of Switching from BRAF/MEK Inhibition to Immune Checkpoint Inhibition Before Secondary Resistance in Metastatic Melanoma: A EUMelaReg Real-world Study." Annals of Oncology 36 (2025): S963. https://doi.org/10.1016/j.annonc.2025.08.2251.

MLA (9th ed.) Citation

Weichenthal, M., et al. "1623P Impact of Switching from BRAF/MEK Inhibition to Immune Checkpoint Inhibition Before Secondary Resistance in Metastatic Melanoma: A EUMelaReg Real-world Study." Annals of Oncology, vol. 36, 2025, p. S963, https://doi.org/10.1016/j.annonc.2025.08.2251.